Ipsen: Ipsen to present elafibranor data from phase II ELMWOOD clinical study at EASL Congress 2025 on May 10, 2025
Ipsen, will be presenting data from the late─breaking abstract on elafibranor in the investigational phase II ELMWOOD study at the European Association for the Study of the Liver Congress (EASL
Read full article »
Ipsen is a France-based biopharmaceutical company that develops and commercializes generic medicines for the treatment of cancer and neurogenerative disease.
Read more